Isnt it al_老虎社区_美港股上老虎

2021-12-01

Isnt it already a little too late with the numerous other vaccines already hitting the world for a while now?

Novavax Can Still Find Growth Opportunities Abroad

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603058472,"tweetId":"603058472","gmtCreate":1638344118560,"gmtModify":1638344119035,"author":{"id":3575345755723136,"idStr":"3575345755723136","authorId":3575345755723136,"authorIdStr":"3575345755723136","name":"JayD","avatar":"https://static.tigerbbs.com/351a615bb9b62fee1934015c7f6d857b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":33,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Isnt it already a little too late with the numerous other vaccines already hitting the world for a while now?</body></html>","htmlText":"<html><head></head><body>Isnt it already a little too late with the numerous other vaccines already hitting the world for a while now?</body></html>","text":"Isnt it already a little too late with the numerous other vaccines already hitting the world for a while now?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603058472","repostId":1164737284,"repostType":4,"repost":{"id":"1164737284","pubTimestamp":1638343312,"share":"https://www.laohu8.com/m/news/1164737284?lang=&edition=full","pubTime":"2021-12-01 15:21","market":"us","language":"en","title":"Novavax Can Still Find Growth Opportunities Abroad","url":"https://stock-news.laohu8.com/highlight/detail?id=1164737284","media":"InvestorPlace","summary":"NVAX stock has been wobbly in 2021, but next year could provide a breakout moment","content":"Of all the U.S.-based companies developing a Covid-19 vaccine candidate,Novavax(NASDAQ:NVAX) certainly hasn’t been the most commercially successful one. As a result, the performance of NVAX stock for much of 2021 has been lackluster. Yet, Novavax’s progress shouldn’t only be measured in the U.S. Remember, Covid-19 is an international problem and vaccines can be commercialized in different regional markets.\nA challenge for Novavax has been getting its Covid-19 vaccine candidate approved, or at least considered, by regulators in these markets abroad.\nFortunately, as we’ll see, the company has demonstrated success in this endeavor. Hopefully, this will bring more investors into the bull camp, thereby boosting the price of NVAX stock.\nNVAX&nbsp;Stock at a Glance\nThere’s no such thing as a guaranteed floor in technical stock analysis. The only exception might be zero, as a stock can’t go any lower than that. Still, around $120 appears to be a pretty solid floor, or at least a support level, for NVAX stock. Indeed, the stock bounced off of that level in January, May and October of this year.\nThe biggest of those three bounces took place early in the year, when the Novavax share price hit a 52-week high of $331.68. This event demonstrated how high the stock is capable of going, though in theory there’s really no limit. Heading into late November, NVAX stock was trading at approximately $200.\nTechnicians might say that the stock is somewhere in the middle of its defined range. Watch closely for a breakout above $275, which could galvanize the buyers and perpetuate a long-term rally.\nMaking Strides in South Korea\nAgain, we must emphasize that the battle against Covid-19 is taking place on multiple regional fronts.\nFor instance, Novavax appears to be making progress towards regulatory approval in South Korea. Specifically, Novavax, along with South Korea biotechnology company&nbsp;SK Bioscience,submitted&nbsp;a Biologics License Application (BLA) for Novavax’ Covid-19 vaccine toSouth Korea’sMinistry of Food and Drug Safety (MFDS). Known as NVX-CoV2373, Novavax’s Covid-19 vaccine with a&nbsp;Matrix-M adjuvant&nbsp;is the first protein-based Covid-19 vaccine to be submitted for a BLA in South Korea.\nIt’s been a long-awaited event, as Novavax and SK Bioscience initiated the rolling submission process for NVX-CoV2373 to the MFDS back in April of this year.\nMoreover, full approval could be granted next, as this BLA submission to the MFDS represents the final review stage for authorization of NVX-CoV2373 in South Korea.\nStanley C. Erck, the president and CEO of Novavax, observed the broader implications of this BLA submission: “Today’s submission reflects the first BLA submission for full approval of our COVID-19 vaccine anywhere in the world, with more anticipated to follow,”Erck explained.\nAn Announcement in Europe\nMeanwhile, Novavax&nbsp;revealed&nbsp;that the European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for NVX-CoV2373. If everything goes as planned, Novavax’s Covid-19 vaccine will be marketed in the European Union under the brand name Nuvaxovid.\nThis CMA application is just one of many regulatory filings that Novavax has made.\nOther filings have been made in theUnited Kingdom,&nbsp;Australia,&nbsp;New Zealand and&nbsp;Canada. Plus, Novavax filed to get its Covid-19 vaccine candidate approved by the World Health Organization (WHO).\nYet, some stakeholders might consider the EMA application by itself to be particularly impactful for Novavax.\nWithout a doubt, securing a marketing authorization in Europe could open the door to significant revenue streams for Novavax.\nThe Takeaway\nOpportunities to combat the Covid-19 pandemic exist in multiple regions of the world. There’s no denying that Novavax isn’t the most successful Covid-19 vaccine developer in the U.S. I currently give NVAX stock a “B” in myPortfolio Grader.\nHowever, don’t dismiss the company’s progress abroad.\nInternational regulatory wins in the coming months would help Novavax advance its Covid-19 vaccine candidate, and thereby provide greater value to the shareholders.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Can Still Find Growth Opportunities Abroad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Can Still Find Growth Opportunities Abroad\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 15:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/nvax-stock-can-still-find-growth-opportunities-abroad/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nOf all the U.S.-based companies developing a Covid-19 vaccine candidate,Novavax(NASDAQ:NVAX) certainly hasn’t been the most commercially successful one. As a result, the performance of NVAX stock for ...\n\n<a href=\"https://investorplace.com/2021/11/nvax-stock-can-still-find-growth-opportunities-abroad/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/11/nvax-stock-can-still-find-growth-opportunities-abroad/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164737284","content_text":"Of all the U.S.-based companies developing a Covid-19 vaccine candidate,Novavax(NASDAQ:NVAX) certainly hasn’t been the most commercially successful one. As a result, the performance of NVAX stock for much of 2021 has been lackluster. Yet, Novavax’s progress shouldn’t only be measured in the U.S. Remember, Covid-19 is an international problem and vaccines can be commercialized in different regional markets.\nA challenge for Novavax has been getting its Covid-19 vaccine candidate approved, or at least considered, by regulators in these markets abroad.\nFortunately, as we’ll see, the company has demonstrated success in this endeavor. Hopefully, this will bring more investors into the bull camp, thereby boosting the price of NVAX stock.\nNVAX Stock at a Glance\nThere’s no such thing as a guaranteed floor in technical stock analysis. The only exception might be zero, as a stock can’t go any lower than that. Still, around $120 appears to be a pretty solid floor, or at least a support level, for NVAX stock. Indeed, the stock bounced off of that level in January, May and October of this year.\nThe biggest of those three bounces took place early in the year, when the Novavax share price hit a 52-week high of $331.68. This event demonstrated how high the stock is capable of going, though in theory there’s really no limit. Heading into late November, NVAX stock was trading at approximately $200.\nTechnicians might say that the stock is somewhere in the middle of its defined range. Watch closely for a breakout above $275, which could galvanize the buyers and perpetuate a long-term rally.\nMaking Strides in South Korea\nAgain, we must emphasize that the battle against Covid-19 is taking place on multiple regional fronts.\nFor instance, Novavax appears to be making progress towards regulatory approval in South Korea. Specifically, Novavax, along with South Korea biotechnology company SK Bioscience,submitted a Biologics License Application (BLA) for Novavax’ Covid-19 vaccine toSouth Korea’sMinistry of Food and Drug Safety (MFDS). Known as NVX-CoV2373, Novavax’s Covid-19 vaccine with a Matrix-M adjuvant is the first protein-based Covid-19 vaccine to be submitted for a BLA in South Korea.\nIt’s been a long-awaited event, as Novavax and SK Bioscience initiated the rolling submission process for NVX-CoV2373 to the MFDS back in April of this year.\nMoreover, full approval could be granted next, as this BLA submission to the MFDS represents the final review stage for authorization of NVX-CoV2373 in South Korea.\nStanley C. Erck, the president and CEO of Novavax, observed the broader implications of this BLA submission: “Today’s submission reflects the first BLA submission for full approval of our COVID-19 vaccine anywhere in the world, with more anticipated to follow,”Erck explained.\nAn Announcement in Europe\nMeanwhile, Novavax revealed that the European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for NVX-CoV2373. If everything goes as planned, Novavax’s Covid-19 vaccine will be marketed in the European Union under the brand name Nuvaxovid.\nThis CMA application is just one of many regulatory filings that Novavax has made.\nOther filings have been made in theUnited Kingdom, Australia, New Zealand and Canada. Plus, Novavax filed to get its Covid-19 vaccine candidate approved by the World Health Organization (WHO).\nYet, some stakeholders might consider the EMA application by itself to be particularly impactful for Novavax.\nWithout a doubt, securing a marketing authorization in Europe could open the door to significant revenue streams for Novavax.\nThe Takeaway\nOpportunities to combat the Covid-19 pandemic exist in multiple regions of the world. There’s no denying that Novavax isn’t the most successful Covid-19 vaccine developer in the U.S. I currently give NVAX stock a “B” in myPortfolio Grader.\nHowever, don’t dismiss the company’s progress abroad.\nInternational regulatory wins in the coming months would help Novavax advance its Covid-19 vaccine candidate, and thereby provide greater value to the shareholders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":293,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":90,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603058472"}